Featured
Status
Health Topics
Any Category-
- Amino Acids, Peptides, and Proteins 103
- Biological Factors 25
- Biomedical and Dental Materials 1
- Carbohydrates 16
- Chemical Actions and Uses 63
- Complex Mixtures 32
- Enzymes and Coenzymes 11
- Heterocyclic Compounds 130
- Hormones, Hormone Substitutes, and Hormone Antagonists 31
- Inorganic Chemicals 47
- Lipids 12
- Macromolecular Substances 2
- Nucleic Acids, Nucleotides, and Nucleosides 24
- Organic Chemicals 202
- Pharmaceutical Preparations 10
- Polycyclic Compounds 62
Search Clinical Trials
Completed
Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults (External Link)
Double blind, randomized, controlled, dose-escalation Phase 1 clinical trial in hookworm-exposed adults aged 18 to 50 years living in the area of Lambaréné, Gabon. Participants will receive three doses of …
Baylor Role:
Lead Sponsor
Recruiting
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (External Link)
In this study the first step is to collect blood from the patient to make the GINAKIT cells. Once the GINAKIT cells are made they will be administered to the …
Baylor Role:
Lead Sponsor
Recruiting
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM (External Link)
This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy in recurrent glioblastoma multiforme or anaplastic astrocytoma. …
Completed
Entolimod, an Adjuvant for Vaccine Augmentation (External Link)
This is a single-blind (participants are blinded), pilot study with no therapeutic or diagnostic intent and limited drug exposure. The study will be conducted at Baylor College of Medicine in …
Baylor Role:
Lead Sponsor
Withdrawn
Safe Return and Disposal of Unused Opioids (External Link)
Participants identified by the PI and participating research staff/coordinators that will receive opioids following discharge will be approached. The participant information sheet will be provided to the parents/legal guardian and …
Baylor Role:
Lead Sponsor
Completed
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta (External Link)
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in …
Baylor Role:
Lead Sponsor
Completed
Effect of Monochromatic Light on Incidence of Emergence Delirium in Children (External Link)
Emergence delirium/emergence agitation (ED/EA) is a behavioral phenomenon of unclear etiology consisting of short lived behavioral changes that can be both traumatic to families and pose a safety risk to …
Baylor Role:
Lead Sponsor
Recruiting
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (External Link)
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the …
Baylor Role:
Lead Sponsor
Active, Not Recruiting
Meclizine for Hepatocellular Carcinoma (External Link)
The constitutive androstane receptor (CAR, NR1I3) is a nuclear receptor that plays a central role in hepatic detoxification of potentially toxic compounds, or xenobiotics. Chronic CAR activation by specific agonists …
Completed
Review of Diagnostic Yield of MRI Brain Results in Children Under Age 3 Years (External Link)
On December 14, 2016 the FDA issued a warning regarding elective anesthetics in children under three years of age. While a single, short exposure to general anesthesia may not have …
Baylor Role:
Lead Sponsor